Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on Residual neuromuscular blockade following electroconvulsive therapy.

Anaesthesia and intensive care·2026
Same author

Negative Contextual Valence Unmasks Altered Counterfactual Decision-Making in Major Depressive Disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Relapse Prevention After Successful ECT for Depression: The Role of Lithium and Continuation/Maintenance ECT.

The American journal of psychiatry·2026
Same author

Protein expression is associated with brain white matter in Veterans with Bipolar disorder and suicide attempts.

Brain, behavior, and immunity·2026
Same author

Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach.

Translational psychiatry·2026
Same author

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

2026 Annual Meeting: President-Elect Address.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: CEO and Medical Director's Address.

The American journal of psychiatry·2026
Same journal

Reports to the Membership.

The American journal of psychiatry·2026
Same journal

Convergent Metabolic Dysregulations But Divergent Contributing Pathways Across Severe Mental Disorders: The Power of Combining Genetics and Metabolomics.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: Presidential Address.

The American journal of psychiatry·2026
Same journal

Represcribing Previously Used Antipsychotics: Response to So.

The American journal of psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

ECT in treatment-resistant depression.

Charles H Kellner1, Robert M Greenberg, James W Murrough

  • 1Departments of Psychiatry and Anesthesiology, Mount Sinai School of Medicine, NY, USA. charles.kellner@mssm.edu

The American Journal of Psychiatry
|December 6, 2012
PubMed
Summary
This summary is machine-generated.

Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression, despite ongoing controversy. This review clarifies modern ECT techniques and addresses common misconceptions for healthcare professionals.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Related Experiment Videos

Last Updated: May 16, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Treatments

Background:

  • Electroconvulsive therapy (ECT) has been used for 75 years.
  • ECT is a critical treatment for severe and treatment-resistant depression.
  • Despite its efficacy for severe mood and psychotic disorders, ECT remains controversial due to misperceptions and lack of familiarity with modern techniques.

Purpose of the Study:

  • To present an illustrative case for which ECT is indicated.
  • To review the basic and clinical science behind ECT's mechanism of action.
  • To discuss clinical administration issues, including the consent process.

Main Methods:

  • Case presentation of a patient indicated for ECT.
  • Review of scientific literature on ECT mechanisms.
  • Discussion of clinical protocols and ethical considerations.

Main Results:

  • ECT is the most effective acute treatment for severe mood and psychotic disorders.
  • Modern ECT techniques are safe and effective when administered correctly.
  • Addressing misconceptions is crucial for wider acceptance and appropriate utilization.

Conclusions:

  • ECT remains a vital and effective treatment option for severe psychiatric conditions.
  • Increased understanding of modern ECT techniques and mechanisms can alleviate controversy.
  • Proper patient selection and informed consent are paramount for ECT administration.